Carsten Nieder1,2, Ellinor C Haukland3,2, Bard Mannsaker3, Rosalba Yobuta3. 1. Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway; carsten.nieder@nlsh.no. 2. Department of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway. 3. Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway.
Abstract
BACKGROUND/AIM: The study aimed to evaluate practice changes in the time period of the early wave of the COVID-19 pandemic. PATIENTS AND METHODS: This was a retrospective single institution study. We defined palliative radiotherapy (PRT) initiated before Saturday, March 14th as pre-COVID and PRT initiated later as during-COVID (through June 30th). RESULTS: National COVID-19 recommendations led to a significant decrease in PRT with 10 or more fractions, while re-irradiation and radiotherapy during the final 30 days of life were equally common before and after these recommendations had been issued in March 2020. CONCLUSION: Rapid adoption of modified PRT regimens was feasible. However, the challenge of overtreatment in the final phase of the disease, due to inaccurate survival prediction, persisted. Copyright
BACKGROUND/AIM: The study aimed to evaluate practice changes in the time period of the early wave of the COVID-19 pandemic. PATIENTS AND METHODS: This was a retrospective single institution study. We defined palliative radiotherapy (PRT) initiated before Saturday, March 14th as pre-COVID and PRT initiated later as during-COVID (through June 30th). RESULTS: National COVID-19 recommendations led to a significant decrease in PRT with 10 or more fractions, while re-irradiation and radiotherapy during the final 30 days of life were equally common before and after these recommendations had been issued in March 2020. CONCLUSION: Rapid adoption of modified PRT regimens was feasible. However, the challenge of overtreatment in the final phase of the disease, due to inaccurate survival prediction, persisted. Copyright
Authors: Kent Angelo; Jan Norum; Astrid Dalhaug; Adam Pawinski; Gro Aandahl; Ellinor Haukland; Kirsten Engljähringer; Carsten Nieder Journal: Anticancer Res Date: 2014-02 Impact factor: 2.480
Authors: C Nieder; K Marienhagen; A Dalhaug; G Aandahl; E Haukland; A Pawinski Journal: Clin Oncol (R Coll Radiol) Date: 2014-04-02 Impact factor: 4.126
Authors: Vérane Achard; Daniel M Aebersold; Abdelkarim S Allal; Nicolaus Andratschke; Brigitta G Baumert; Karl T Beer; Michael Betz; Thomas Breuneval; Stephan Bodis; Berardino de Bari; Robert Förster; Alessandra Franzetti-Pellanda; Matthias Guckenberger; Evelyn Herrmann; Constance Huck; Kaouthar Khanfir; Oscar Matzinger; Nicolas Peguret; Gianfranco Pesce; Paul M Putora; Christiane Reuter; Antonella Richetti; Hansjörg Vees; Conny Vrieling; Kathrin Zaugg; Frank Zimmermann; Daniel R Zwahlen; Pelagia Tsoutsou; Thomas Zilli Journal: Radiother Oncol Date: 2020-06-06 Impact factor: 6.280
Authors: Matthias Guckenberger; Claus Belka; Andrea Bezjak; Jeffrey Bradley; Megan E Daly; Dirk DeRuysscher; Rafal Dziadziuszko; Corinne Faivre-Finn; Michael Flentje; Elizabeth Gore; Kristin A Higgins; Puneeth Iyengar; Brian D Kavanagh; Sameera Kumar; Cecile Le Pechoux; Yolande Lievens; Karin Lindberg; Fiona McDonald; Sara Ramella; Ramesh Rengan; Umberto Ricardi; Andreas Rimner; George B Rodrigues; Steven E Schild; Suresh Senan; Charles B Simone; Ben J Slotman; Martin Stuschke; Greg Videtic; Joachim Widder; Sue S Yom; David Palma Journal: Int J Radiat Oncol Biol Phys Date: 2020-07-15 Impact factor: 8.013